contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


brain-as-brain-announces-first-day-of-trading-in-new-shares-from-the-to-4-warrant-exercise-and-the-related-directed-issue

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.

Brain+

Copenhagen, Denmark, 7 October 2024- Brain+ A/S (Nasdaq First North: BRAINP)On 1 October 2024, Brain+ A/S ("Brain+" or "the Company") announced that 38,522,165 of its warrants of series TO4 ...

<div class="abstract">Copenhagen, Denmark, 7 October 2024- Brain+ A/S (Nasdaq First North: BRAINP)On 1 October 2024, Brain+ A/S ("Brain+" or "the Company") announced that 38,522,165 of its warrants of series TO4 (the `Warrants') had been exercised for subscription of 38,522,165 new shares and the decision to carry out a directed issue of 2,517,179 new shares to guarantors of the Warrant exercise (the "Directed Issue"). The TO 4 warrants were issued in connection with Brain+' unit rights issue in June 2024. The new shares from both the Warrant exercise and the Directed Issue have now been registered with the Danish Business Authority and admitted for trading on Nasdaq First North Copenhagen from 8 October 2024.</div>After the completion and registration of the Warrant exercise and the Directed Issue with the Danish Business Authority, the number of shares in Brain+ have increased by 41,039,344 shares, from 171,501,141 shares to 212,540,485 shares, and the Company's nominal share capital have increased by DKK 3,283,147.52, from DKK 13,720,091.28 to DKK 17,003,238.80.After registration with the Danish Business Authority, all the new shares from both the Warrant exercise and the Directed Issue have now also been admitted for trading on Nasdaq First North Copenhagen under the ISIN-code for Brain+ shares: DK0061670205.The first day of trading of the new shares will be 8 October 2024.Advisors In connection with the unit rights issue including the issue and exercise of warrants of series TO 4, Sedermera Corporate Finance AB act as financial advisors to Brain+. Markets &amp; Corporate Law Nordic AB acts as legal advisor. Nordic Issuing AB is the issuing agent.For more information about the warrant exercise, please contact:Sedermera Corporate Finance AB Phone: +46 (0) 40 615 14 10 E-mail:&nbsp;cf@sedermera.se www.sedermera.seFor more information about Brain+, please contact:Kim Baden-Kristensen, CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hanne Vissing Leth, CFO Phone: +45 31 39 33 17&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Phone: +45 53 88 99 02 E-mail:&nbsp;kim@brain-plus.com&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; E-mail: hanne@brain-plus.comwww.brain-plus.comCertified AdviserKeswick Global AG Phone: +43 1&nbsp;740&nbsp;408 045 E-mail:&nbsp;info@keswickglobal.comBrain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia in 2030.

Brain+ A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon continues to grow in Sweden

Stay up to date with our newsletter